We happily present new additions to the LinXis scientific portfolio
We are proud to welcome Guus van Dongen as our CSO.
By developing first-in-class targeted medicines for the treatment of fibrosis we are sailing into uncharted waters
LinXis continuously works to strengthen its intellectual property position.
